Cyclin D1, and to a lesser extent the other D-type cyclins, is frequently deregulated in cancer
and is a biomarker of cancer phenotype and disease progression. The ability of these …

Entry and progression through mitosis has traditionally been linked directly to the activity of
cyclin-dependent kinase 1 (Cdk1). In this study we utilized low doses of the Cdk1-specific …

In breast cancer, cyclins D1 and E and the cyclin‐dependent kinase inhibitors p21 (Waf1/Cip1)and
p27 (Kip1) are important in cell‐cycle control and as potential oncogenes or tumor …

The role of the androgen receptor (AR) in estrogen receptor (ER)-α-positive breast cancer is
controversial, constraining implementation of AR-directed therapies. Using a diverse, …

Estrogen is necessary for the normal growth and development of breast tissue, but high levels
of estrogen are a major risk factor for breast cancer. One mechanism by which estrogen …

Cyclin E2, but not cyclin E1, is included in several gene signatures that predict disease
progression in either tamoxifen-resistant or metastatic breast cancer. We therefore examined the …

The highly conserved E-type cyclins are core components of the cell cycle machinery,
facilitating the transition into S phase through activation of the cyclin dependent kinases, and …

… Anshabo 1 , Neil Portman 3 4 , Elgene Lim 3 4 , Wayne Tilley 5 , C. Elizabeth Caldon 3 4 ,
… As shown by yeast two-hybrid assays, CDK2–cyclin-A complex directly interacts with the C …

Three inhibitors of CDK4/6 kinases were recently FDA approved for use in combination with
endocrine therapy, and they significantly increase the progression-free survival of patients …

Endocrine therapy resistance frequently develops in estrogen receptor positive (ER+) breast
cancer, but the underlying molecular mechanisms are largely unknown. Here, we show that …